Mn Services Vermogensbeheer B.V. Trims Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mn Services Vermogensbeheer B.V. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,060 shares of the company's stock after selling 2,400 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in IDEXX Laboratories were worth $12,624,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Empowered Funds LLC raised its holdings in shares of IDEXX Laboratories by 10.2% in the fourth quarter. Empowered Funds LLC now owns 1,443 shares of the company's stock valued at $597,000 after buying an additional 133 shares during the last quarter. Asset Management One Co. Ltd. increased its position in IDEXX Laboratories by 6.1% in the 4th quarter. Asset Management One Co. Ltd. now owns 52,844 shares of the company's stock valued at $21,927,000 after acquiring an additional 3,057 shares during the period. Allworth Financial LP raised its stake in IDEXX Laboratories by 61.2% during the 4th quarter. Allworth Financial LP now owns 1,507 shares of the company's stock valued at $649,000 after acquiring an additional 572 shares during the last quarter. Sheaff Brock Investment Advisors LLC lifted its position in IDEXX Laboratories by 1.7% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 3,036 shares of the company's stock worth $1,255,000 after acquiring an additional 51 shares during the period. Finally, Blue Zone Wealth Advisors LLC acquired a new stake in IDEXX Laboratories during the 4th quarter worth approximately $3,958,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

IDXX traded down $8.18 on Tuesday, hitting $520.59. 430,579 shares of the company were exchanged, compared to its average volume of 649,180. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $540.33. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The firm has a market capitalization of $41.87 billion, a P/E ratio of 48.87, a price-to-earnings-growth ratio of 3.86 and a beta of 1.55. The business's fifty day moving average is $476.46 and its 200 day moving average is $445.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the prior year, the firm posted $2.71 EPS. The company's revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on IDXX. Leerink Partners boosted their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Stifel Nicolaus raised their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Finally, Morgan Stanley boosted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $546.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.